Arbutus Biopharma Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma or view top-rated stocks.

Wall Street analysts have given Arbutus Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arbutus Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Arbutus Biopharma saw a decrease in short interest in the month of August. As of August 13th, there was short interest totaling 4,150,000 shares, a decrease of 26.2% from the July 29th total of 5,620,000 shares. Based on an average daily trading volume, of 1,650,000 shares, the short-interest ratio is currently 2.5 days. Currently, 5.2% of the company's stock are sold short.
View Arbutus Biopharma's Short Interest.

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arbutus Biopharma.

Arbutus Biopharma Co. (NASDAQ:ABUS) issued its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The biopharmaceutical company had revenue of $2.33 million for the quarter, compared to the consensus estimate of $2.07 million.
View Arbutus Biopharma's earnings history.

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABUS shares have increased by 68.6% and is now trading at $4.35.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued 1 year price targets for Arbutus Biopharma's stock. Their forecasts range from $5.00 to $10.00. On average, they expect Arbutus Biopharma's stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for Arbutus Biopharma or view top-rated stocks among Wall Street analysts.

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Arbutus Biopharma include Dynavax Technologies (DVAX), IVERIC bio (ISEE), uniQure (QURE), Dicerna Pharmaceuticals (DRNA), Zymeworks (ZYME), Global Blood Therapeutics (GBT), MorphoSys (MOR), Prelude Therapeutics (PRLD), Nurix Therapeutics (NRIX), Generation Bio (GBIO), Amneal Pharmaceuticals (AMRX), Kadmon (KDMN), Tango Therapeutics (TNGX), Supernus Pharmaceuticals (SUPN) and Day One Biopharmaceuticals (DAWN).
View all of ABUS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Arbutus Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.88%), Vanguard Group Inc. (3.77%), Geode Capital Management LLC (1.30%), State Street Corp (1.17%), Point72 Asset Management L.P. (1.01%) and Northern Trust Corp (0.73%).
View institutional ownership trends for Arbutus Biopharma.

ABUS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Cubist Systematic Strategies LLC, Qube Research & Technologies Ltd, SG3 Management LLC, Point72 Asset Management L.P., Citigroup Inc., and Credit Suisse AG.
View insider buying and selling activity for Arbutus Biopharma or view top insider-selling stocks.

ABUS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Geode Capital Management LLC, Northern Trust Corp, Deutsche Bank AG, Group One Trading L.P., and Nuveen Asset Management LLC.
View insider buying and selling activity for Arbutus Biopharma or or view top insider-buying stocks.

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABUS stock can currently be purchased for approximately $4.35.

Arbutus Biopharma has a market capitalization of $431.35 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63,740,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

Arbutus Biopharma employs 77 workers across the globe.

Arbutus Biopharma was founded in 1992.

The official website for Arbutus Biopharma is www.arbutusbio.com.

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914 or via email at [email protected].